Newsroom

NEW publication on the analytical performance of Papilloplex HR-HPV

19 June 2019

The accurate detection and genotyping of high-risk human papillomavirus (HR-HPV) is critical for cervical cancer screening and epidemiological investigations. GeneFirst Papilloplex® HRHPV is a new CE-IVD marked real-time PCR test, based on patented Multiplex Probe Amplification (MPA) technology. Papilloplex® HR-HPV provides the simultaneous detection and differentiation of 14 HR-HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68a/b) in a single closed-tube reaction ensuring rapid, cost effective and contamination free results. In this study, the analytical performance characteristics in terms of the assay’s sensitivity, specificity, range, reproducibility and cross-reactivity were evaluated. Papilloplex® HR-HPV provided sensitive detection and differentiation of 14 HR-HPV types with highly reproducible results. The differential HR-HPV specificity and sensitivity was further confirmed through the participation in the WHO HPV Laboratory Network Proficiency Study (2014). Overall, GeneFirst Papilloplex® HR-HPV assay demonstrated a robust analytical performance with reproducible and reliable results in the detection of HR-HPV genotypes. Read More

GeneFirst wins €2.9m Horizon 2020 grant to deliver predictive diagnostic panel for HPV infections evolving into cervical cancer

1 October 2018

Oxford, UK. GeneFirst Limited, the leader in delivering innovative solutions for HPV testing today announces the award of a €2.9 million up-front grant from the SME Instrument of the European Commission’s Horizon 2020 Programme to develop a predictive assay panel that can discriminate those hrHPV infections at increased risk of disease progression. This work will be conducted with GeneFirst’s joint collaborator, Hiantis S.r.l, based in Milan, Italy, who has extensive experience in clinical and laboratory research. Read more

26 October 2017

Oxford, UK. GeneFirst Limited, the leader in delivering Next Generation Sequencing solutions for liquid biopsy testing, today announces the award of a 12-month grant of £457,000 from Innovate UK’s Open Programme Round 3 to continue development of DNA sequencing technology to improve cancer treatment through better detection of cancer mutations in blood. Read more...

28th September 2017

Oxford, UK. GeneFirst Limited, the leader in delivering Next Generation Sequencing solutions for liquid biopsy testing, today announces the award of a two year grant of £350,000 from Innovate UK’s Shanghai-UK Challenge Programme to develop a non-invasive test for cancer gene mutations with  Fosun Med-Tech.

 

The Innovate UK funding is a joint UK-Shanghai competition to identify new and novel products, processes or services drawn from any technology, engineering or industrial area. Under this highly competitive grant, GeneFirst will use its leading and proprietary ATOM-seq™ technology to deliver an NGS assay panel to detect cancer gene mutations in liquid biopsy, enabling clinically relevant cancer genotyping by non-invasive means. Read more...

Please reload

+44 (0) 1865 407400

Culham Science Centre, Oxfordshire, UK.  OX14 3DB

© 2019 GeneFirst Ltd.  All rights reserved.  Privacy Policy |